Such an acquisition permits a continuous and comprehensive comparison of the distribution of CD8+ T cells and further extends to CD8+ TRM cells, offering a window into the adaptive remodeling of the tumor microenvironment under immunotherapy. The gene discussed is CD8A; the disease is neoplasm.